You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIrbesartan
Accession NumberDB01029  (APRD00413)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionIrbesartan is an angiotensin receptor blocker (ARB) used mainly for the treatment of hypertension. It competes with angiotensin II for binding at the AT1 receptor subtype. Unlike ACE inhibitors, ARBs do not have the adverse effect of dry cough. The use of ARBs is pending revision due to findings from several clinical trials suggesting that this class of drugs may be associated with a small increased risk of cancer.
Structure
Thumb
Synonyms
2-Butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
Avapro
BMS 186295
Irbesartan
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Irbesartantablet150 mgoralActavis Pharma Company2011-03-21Not applicableCanada
Act Irbesartantablet300 mgoralActavis Pharma Company2011-03-21Not applicableCanada
Act Irbesartantablet75 mgoralActavis Pharma Company2011-03-21Not applicableCanada
AprovelTablet75 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelFilm-coated tablet75 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelFilm-coated tablet300 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet150 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelFilm-coated tablet300 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelFilm-coated tablet75 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet300 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelFilm-coated tablet150 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelFilm-coated tablet300 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet300 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet150 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelFilm-coated tablet75 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelFilm-coated tablet75 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet300 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelFilm-coated tablet300 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelFilm-coated tablet150 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelFilm-coated tablet150 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet300 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet75 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelFilm-coated tablet75 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelFilm-coated tablet75 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet150 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelFilm-coated tablet75 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelFilm-coated tablet150 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelFilm-coated tablet300 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet75 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet300 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelFilm-coated tablet150 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelFilm-coated tablet300 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet75 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelFilm-coated tablet75 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelFilm-coated tablet150 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelFilm-coated tablet300 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet150 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelFilm-coated tablet150 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelFilm-coated tablet300 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet150 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelTablet75 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
AprovelFilm-coated tablet150 mgOral useSanofi Clir Snc1997-08-27Not applicableEu
Auro-irbesartantablet150 mgoralAuro Pharma Inc2013-07-08Not applicableCanada
Auro-irbesartantablet300 mgoralAuro Pharma Inc2013-07-08Not applicableCanada
Auro-irbesartantablet75 mgoralAuro Pharma Inc2013-07-08Not applicableCanada
Ava-irbesartantablet75 mgoralAvanstra Inc2011-11-232014-08-21Canada
Ava-irbesartantablet150 mgoralAvanstra Inc2011-11-232014-08-21Canada
Ava-irbesartantablet300 mgoralAvanstra Inc2011-11-232014-08-21Canada
Avaprotablet150 mg/1oralLake Erie Medical DBA Quality Care Products LLC2013-01-01Not applicableUs
Avaprotablet75 mg/1oralSanofi Aventis U.S. Llc2013-01-01Not applicableUs
Avaprotablet300 mgoralSanofi Aventis Canada Inc1998-07-22Not applicableCanada
Avaprotablet150 mg/1oralbryant ranch prepack1997-09-30Not applicableUs
Avaprotablet300 mg/1oralBristol Myers Squibb Company1997-09-302016-03-31Us
Avaprotablet150 mg/1oralPhysicians Total Care, Inc.2000-11-21Not applicableUs
Avaprotablet150 mg/1oralSanofi Aventis U.S. Llc2013-01-01Not applicableUs
Avaprotablet300 mg/1oralbryant ranch prepack1997-09-30Not applicableUs
Avaprotablet300 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-23Not applicableUs
Avaprotablet300 mg/1oralPhysicians Total Care, Inc.2004-05-10Not applicableUs
Avaprotablet300 mg/1oralSanofi Aventis U.S. Llc2013-01-01Not applicableUs
Avaprotablet75 mgoralSanofi Aventis Canada Inc1998-06-22Not applicableCanada
Avaprotablet150 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-03-23Not applicableUs
Avaprotablet150 mg/1oralCardinal Health1997-09-30Not applicableUs
Avaprotablet150 mg/1oralBristol Myers Squibb Company1997-09-302016-03-31Us
Avaprotablet150 mgoralSanofi Aventis Canada Inc1998-07-22Not applicableCanada
Bio-irbesartantablet75 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-irbesartantablet150 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-irbesartantablet300 mgoralBiomed PharmaNot applicableNot applicableCanada
Dom-irbesartantablet150 mgoralDominion Pharmacal2013-06-28Not applicableCanada
Dom-irbesartantablet300 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-irbesartantablet75 mgoralDominion PharmacalNot applicableNot applicableCanada
Ipg-irbesartantablet150 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-irbesartantablet300 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-irbesartantablet75 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Irbesartantablet75 mgoralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
Irbesartantablet75 mgoralPro Doc Limitee2011-05-27Not applicableCanada
Irbesartantablet75 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Irbesartantablet75 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Irbesartantablet75 mgoralSanis Health Inc2011-10-18Not applicableCanada
Irbesartantablet75 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Irbesartantablet150 mgoralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
Irbesartantablet150 mgoralPro Doc Limitee2011-05-27Not applicableCanada
Irbesartantablet150 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Irbesartantablet150 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Irbesartantablet150 mgoralSanis Health Inc2011-10-18Not applicableCanada
Irbesartantablet150 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Irbesartantablet300 mgoralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
Irbesartantablet300 mgoralPro Doc Limitee2011-05-27Not applicableCanada
Irbesartantablet300 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Irbesartantablet300 mgoralSanis Health Inc2011-10-18Not applicableCanada
Irbesartantablet300 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Irbesartantablet300 mgoralJubilant Generics LimitedNot applicableNot applicableCanada
Irbesartan ZentivaFilm-coated tablet150 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaFilm-coated tablet300 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet150 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaFilm-coated tablet75 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaFilm-coated tablet300 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet75 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet300 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaFilm-coated tablet300 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet150 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaFilm-coated tablet75 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaFilm-coated tablet150 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaFilm-coated tablet150 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet150 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaFilm-coated tablet75 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaFilm-coated tablet300 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet75 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet300 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaFilm-coated tablet300 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaFilm-coated tablet150 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaFilm-coated tablet150 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet150 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet300 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaFilm-coated tablet150 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet75 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaFilm-coated tablet75 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaFilm-coated tablet75 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaFilm-coated tablet300 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet300 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaFilm-coated tablet150 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaFilm-coated tablet300 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet150 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet300 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaFilm-coated tablet150 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet75 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaFilm-coated tablet75 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaFilm-coated tablet75 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaFilm-coated tablet300 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaTablet75 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Irbesartan ZentivaFilm-coated tablet75 mgOral useSanofi Aventis Groupe  2007-01-19Not applicableEu
Jamp-irbesartantablet300 mgoralJamp Pharma Corporation2014-01-15Not applicableCanada
Jamp-irbesartantablet75 mgoralJamp Pharma Corporation2014-01-15Not applicableCanada
Jamp-irbesartantablet150 mgoralJamp Pharma Corporation2014-01-15Not applicableCanada
KarveaFilm-coated tablet300 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet300 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaFilm-coated tablet150 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet300 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaFilm-coated tablet150 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet150 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaFilm-coated tablet75 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaFilm-coated tablet75 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaFilm-coated tablet300 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet300 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet75 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaFilm-coated tablet75 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaFilm-coated tablet75 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaFilm-coated tablet150 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet300 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaFilm-coated tablet300 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet150 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaFilm-coated tablet150 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaFilm-coated tablet75 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaFilm-coated tablet300 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet75 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet75 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaFilm-coated tablet150 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaFilm-coated tablet75 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaFilm-coated tablet150 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet75 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet150 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaFilm-coated tablet300 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaFilm-coated tablet150 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaFilm-coated tablet300 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet150 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet75 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaFilm-coated tablet300 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaFilm-coated tablet75 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaFilm-coated tablet300 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet150 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaTablet300 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaFilm-coated tablet75 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
KarveaFilm-coated tablet150 mgOral useSanofi Aventis Groupe1997-08-27Not applicableEu
Mar-irbesartantablet300 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-irbesartantablet75 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-irbesartantablet150 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mint-irbesartantablet300 mgoralMint Pharmaceuticals Inc2015-01-14Not applicableCanada
Mint-irbesartantablet75 mgoralMint Pharmaceuticals Inc2015-01-14Not applicableCanada
Mint-irbesartantablet150 mgoralMint Pharmaceuticals Inc2015-01-14Not applicableCanada
Mylan-irbesartantablet75 mgoralMylan Pharmaceuticals Ulc2011-11-30Not applicableCanada
Mylan-irbesartantablet150 mgoralMylan Pharmaceuticals Ulc2011-11-30Not applicableCanada
Mylan-irbesartantablet300 mgoralMylan Pharmaceuticals Ulc2011-11-30Not applicableCanada
Ntp-irbesartantablet75 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-irbesartantablet150 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-irbesartantablet300 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Pendo-irbesartantablet300 mgoralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
PMS-irbesartantablet75 mgoralPharmascience Inc2011-03-24Not applicableCanada
PMS-irbesartantablet150 mgoralPharmascience Inc2011-03-24Not applicableCanada
PMS-irbesartantablet300 mgoralPharmascience Inc2011-03-24Not applicableCanada
Priva-irbesartantablet150 mgoralPharmapar Inc2016-08-17Not applicableCanada
Priva-irbesartantablet75 mgoralPharmapar Inc2016-05-13Not applicableCanada
Priva-irbesartantablet300 mgoralPharmapar Inc2016-05-13Not applicableCanada
Q-irbesartantablet150 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-irbesartantablet300 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-irbesartantablet75 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Ran-irbesartantablet300 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-07-24Not applicableCanada
Ran-irbesartantablet75 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-07-24Not applicableCanada
Ran-irbesartantablet150 mgoralRanbaxy Pharmaceuticals Canada Inc.2013-07-24Not applicableCanada
Ratio-irbesartantablet75 mgoralTeva Canada Limited2011-03-21Not applicableCanada
Ratio-irbesartantablet150 mgoralTeva Canada Limited2011-03-21Not applicableCanada
Ratio-irbesartantablet300 mgoralTeva Canada Limited2011-03-21Not applicableCanada
Riva-irbesartantablet300 mgoralLaboratoire Riva Inc2014-12-03Not applicableCanada
Riva-irbesartantablet75 mgoralLaboratoire Riva Inc2014-12-03Not applicableCanada
Riva-irbesartantablet150 mgoralLaboratoire Riva Inc2014-12-03Not applicableCanada
Sandoz Irbesartantablet300 mgoralSandoz Canada Incorporated2011-03-21Not applicableCanada
Sandoz Irbesartantablet75 mgoralSandoz Canada Incorporated2011-03-21Not applicableCanada
Sandoz Irbesartantablet150 mgoralSandoz Canada Incorporated2011-03-21Not applicableCanada
Teva-irbesartantablet75 mgoralTeva Canada Limited2011-03-21Not applicableCanada
Teva-irbesartantablet150 mgoralTeva Canada Limited2011-03-21Not applicableCanada
Teva-irbesartantablet300 mgoralTeva Canada Limited2011-03-21Not applicableCanada
Van-irbesartantablet75 mgoralVanc Pharmaceuticals Inc2015-06-08Not applicableCanada
Van-irbesartantablet150 mgoralVanc Pharmaceuticals Inc2015-06-08Not applicableCanada
Van-irbesartantablet300 mgoralVanc Pharmaceuticals Inc2015-06-08Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-irbesartantablet75 mgoralApotex Inc2012-09-25Not applicableCanada
Apo-irbesartantablet150 mgoralApotex Inc2012-09-25Not applicableCanada
Apo-irbesartantablet300 mgoralApotex Inc2012-09-25Not applicableCanada
Irbesartantablet300 mg/300mgoralWestminster Pharmaceuticals, Llc2016-02-01Not applicableUs
Irbesartantablet150 mg/1oralSolco healthcare U.S., LLC2012-09-27Not applicableUs
Irbesartantablet, coated150 mg/1oralWatson Laboratories, Inc.2012-10-16Not applicableUs
Irbesartantablet150 mg/1oralbryant ranch prepack2013-05-10Not applicableUs
Irbesartantablet150 mg/1oralUnichem Pharmaceuticals (USA), Inc.2016-04-01Not applicableUs
Irbesartantablet150 mg/1oralAmerican Health Packaging2013-10-162015-12-29Us
Irbesartantablet75 mg/1oralCamber Pharmaceuticals, Inc.2012-09-26Not applicableUs
Irbesartantablet75 mg/1oralRoxane Laboratories, Inc.2012-10-15Not applicableUs
Irbesartantablet75 mg/1oralJubilant Cadista Pharmaceuticals Inc.2015-02-24Not applicableUs
Irbesartantablet300 mg/1oralQualitest Pharmaceuticals2012-09-30Not applicableUs
Irbesartantablet150 mg/1oralLupin Pharmaceuticals, Inc.2012-10-23Not applicableUs
Irbesartantablet75 mg/1oralAurobindo Pharma Limited2012-09-27Not applicableUs
Irbesartantablet300 mg/1oralScie Gen Pharmaceuticals, Inc.2015-12-07Not applicableUs
Irbesartantablet150 mg/1oralMacleods Pharmaceuticals Limited2012-09-27Not applicableUs
Irbesartantablet150 mg/1oralTeva Pharmaceuticals USA Inc2012-03-30Not applicableUs
Irbesartantablet, film coated150 mg/1oralApotex Corp.2012-10-16Not applicableUs
Irbesartantablet300 mg/1oralGolden State Medical Supply, Inc.2016-02-05Not applicableUs
Irbesartantablet150 mg/1oralProficient Rx LP2012-03-30Not applicableUs
Irbesartantablet75 mg/1oralLUPIN LIMITED2012-10-23Not applicableUs
Irbesartantablet300 mg/1oralSolco healthcare U.S., LLC2012-09-27Not applicableUs
Irbesartantablet, coated300 mg/1oralWatson Laboratories, Inc.2012-10-16Not applicableUs
Irbesartantablet150 mg/1oralAmerican Health Packaging2014-12-15Not applicableUs
Irbesartantablet300 mg/1oralUnichem Pharmaceuticals (USA), Inc.2016-04-01Not applicableUs
Irbesartantablet150 mg/1oralCamber Pharmaceuticals, Inc.2012-09-27Not applicableUs
Irbesartantablet150 mg/1oralRoxane Laboratories, Inc.2012-10-15Not applicableUs
Irbesartantablet150 mg/1oralJubilant Cadista Pharmaceuticals Inc.2015-02-24Not applicableUs
Irbesartantablet150 mg/1oralAurobindo Pharma Limited2012-09-27Not applicableUs
Irbesartantablet75 mg/1oralAv Pak2015-10-27Not applicableUs
Irbesartantablet75 mg/1oralAjanta Pharma Limited2015-01-20Not applicableUs
Irbesartantablet300 mg/1oralLupin Pharmaceuticals, Inc.2012-10-23Not applicableUs
Irbesartantablet75 mg/75mgoralWestminster Pharmaceuticals, Llc2016-02-01Not applicableUs
Irbesartantablet300 mg/1oralMacleods Pharmaceuticals Limited2012-09-27Not applicableUs
Irbesartantablet300 mg/1oralTeva Pharmaceuticals USA Inc2013-05-10Not applicableUs
Irbesartantablet, film coated300 mg/1oralApotex Corp.2012-10-16Not applicableUs
Irbesartantablet150 mg/1oralLUPIN LIMITED2012-10-23Not applicableUs
Irbesartantablet75 mg/1oralScie Gen Pharmaceuticals, Inc.2015-12-07Not applicableUs
Irbesartantablet75 mg/1oralQualitest Pharmaceuticals2012-09-30Not applicableUs
Irbesartantablet150 mg/1oralCarilion Materials Management2012-03-30Not applicableUs
Irbesartantablet75 mg/1oralGolden State Medical Supply, Inc.2016-02-05Not applicableUs
Irbesartantablet300 mg/1oralCamber Pharmaceuticals, Inc.2012-09-27Not applicableUs
Irbesartantablet300 mg/1oralRoxane Laboratories, Inc.2012-10-15Not applicableUs
Irbesartantablet300 mg/1oralJubilant Cadista Pharmaceuticals Inc.2015-02-24Not applicableUs
Irbesartantablet300 mg/1oralAurobindo Pharma Limited2012-09-27Not applicableUs
Irbesartantablet150 mg/1oralAv Pak2015-10-27Not applicableUs
Irbesartantablet150 mg/1oralAjanta Pharma Limited2015-01-20Not applicableUs
Irbesartantablet150 mg/1oralLegacy Pharmaceutical Packaging2012-03-30Not applicableUs
Irbesartantablet150 mg/150mgoralWestminster Pharmaceuticals, Llc2016-02-01Not applicableUs
Irbesartantablet75 mg/1oralSolco healthcare U.S., LLC2012-09-27Not applicableUs
Irbesartantablet, coated75 mg/1oralWatson Laboratories, Inc.2012-10-16Not applicableUs
Irbesartantablet300 mg/1oralbryant ranch prepack2012-09-27Not applicableUs
Irbesartantablet75 mg/1oralLupin Pharmaceuticals, Inc.2012-10-23Not applicableUs
Irbesartantablet300 mg/1oralLUPIN LIMITED2012-10-23Not applicableUs
Irbesartantablet150 mg/1oralScie Gen Pharmaceuticals, Inc.2015-12-07Not applicableUs
Irbesartantablet150 mg/1oralQualitest Pharmaceuticals2012-09-30Not applicableUs
Irbesartantablet75 mg/1oralTeva Pharmaceuticals USA Inc2012-03-30Not applicableUs
Irbesartantablet, film coated75 mg/1oralApotex Corp.2012-10-16Not applicableUs
Irbesartantablet150 mg/1oralGolden State Medical Supply, Inc.2016-02-05Not applicableUs
Irbesartantablet75 mg/1oralMacleods Pharmaceuticals Limited2012-09-27Not applicableUs
Irbesartantablet75 mg/1oralUnichem Pharmaceuticals (USA), Inc.2016-04-01Not applicableUs
Irbesartantablet300 mg/1oralAv Pak2015-10-27Not applicableUs
Irbesartantablet300 mg/1oralAjanta Pharma Limited2015-01-20Not applicableUs
Irbesartantablet150 mg/1oralAmerican Health Packaging2013-06-122015-12-29Us
Irbesartan TevaFilm-coated tablet75 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet150 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet300 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet75 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet150 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet150 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet75 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet150 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet300 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet150 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet300 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet75 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet150 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet300 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet75 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet300 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet300 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet75 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet150 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet300 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet300 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet75 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet150 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet75 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet150 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet300 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet75 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet300 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet300 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet75 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet150 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet150 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet300 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet75 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet75 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet150 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet300 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet150 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet300 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet75 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet150 mgOral useTeva B.V.2009-10-30Not applicableEu
Irbesartan TevaFilm-coated tablet75 mgOral useTeva B.V.2009-10-30Not applicableEu
SabervelFilm-coated tablet300 mgOral usePharmathen S.A.2012-04-13Not applicableEu
SabervelFilm-coated tablet75 mgOral usePharmathen S.A.2012-04-13Not applicableEu
SabervelFilm-coated tablet150 mgOral usePharmathen S.A.2012-04-13Not applicableEu
SabervelFilm-coated tablet75 mgOral usePharmathen S.A.2012-04-13Not applicableEu
SabervelFilm-coated tablet150 mgOral usePharmathen S.A.2012-04-13Not applicableEu
SabervelFilm-coated tablet150 mgOral usePharmathen S.A.2012-04-13Not applicableEu
SabervelFilm-coated tablet150 mgOral usePharmathen S.A.2012-04-13Not applicableEu
SabervelFilm-coated tablet75 mgOral usePharmathen S.A.2012-04-13Not applicableEu
SabervelFilm-coated tablet300 mgOral usePharmathen S.A.2012-04-13Not applicableEu
SabervelFilm-coated tablet300 mgOral usePharmathen S.A.2012-04-13Not applicableEu
SabervelFilm-coated tablet300 mgOral usePharmathen S.A.2012-04-13Not applicableEu
SabervelFilm-coated tablet75 mgOral usePharmathen S.A.2012-04-13Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Irbesartan BmsTablet150 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsFilm-coated tablets150 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet75 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsFilm-coated tablets75 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsFilm-coated tablets300 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsFilm-coated tablets150 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet300 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet75 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsFilm-coated tablets75 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet150 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsFilm-coated tablets150 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet75 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsFilm-coated tablets75 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsFilm-coated tablets300 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet300 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsFilm-coated tablets300 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet150 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsFilm-coated tablets75 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet150 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsFilm-coated tablets150 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet75 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsFilm-coated tablets75 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsFilm-coated tablets300 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet300 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsFilm-coated tablets300 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet150 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsFilm-coated tablets150 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet300 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsFilm-coated tablets150 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsFilm-coated tablets75 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet75 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsTablet300 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
Irbesartan BmsFilm-coated tablets300 mgOral useBristol Myers Squibb Pharma Eeig2007-01-19Not applicableEu
International Brands
NameCompany
IrbesarranNot Available
LrbesartanNot Available
Brand mixtures
NameLabellerIngredients
Act Irbesartan/hctActavis Pharma Company
Apo-irbesartan/hctzApotex Inc
Auro-irbesartan HctAuro Pharma Inc
Ava-irbesartan/hctzAvanstra Inc
AvalideSanofi Aventis U.S. Llc
Avalide 150/12.5 mgSanofi Aventis Canada Inc
Avalide 300/12.5 mgSanofi Aventis Canada Inc
Dom-irbesartan-hctzDominion Pharmacal
Irbesartan and HydrochlorothiazideRoxane Laboratories, Inc.
Irbesartan HctSivem Pharmaceuticals Ulc
Irbesartan-hctzPro Doc Limitee
Irbesartan/hctActavis Pharma Company
Irbesartan/hctzSanis Health Inc
Jamp-irbesartan and HydrochlorothiazideJamp Pharma Corporation
Mint-irbesartan/hctzMint Pharmaceuticals Inc
Mylan-irbesartan HctzMylan Pharmaceuticals Ulc
Ntp-irbesartan/hctzTeva Canada Limited
Pendo-irbesartan-hctzPendopharm Division Of De Pharmascience Inc
PMS-irbesartan-hctzPharmascience Inc
Ran-irbesartan HctzRanbaxy Pharmaceuticals Canada Inc.
Ratio-irbesartan HctzTeva Canada Limited
Sandoz Irbesartan HctSandoz Canada Incorporated
Teva-irbesartan/hctzTeva Canada Limited
Van-irbesartan-hctzVanc Pharmaceuticals Inc
SaltsNot Available
Categories
UNIIJ0E2756Z7N
CAS number138402-11-6
WeightAverage: 428.5294
Monoisotopic: 428.232459548
Chemical FormulaC25H28N6O
InChI KeyInChIKey=YOSHYTLCDANDAN-UHFFFAOYSA-N
InChI
InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)
IUPAC Name
2-butyl-3-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one
SMILES
CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as biphenyltetrazoles and derivatives. These are organic compounds containing a biphenyl attached to a tetrazole. A carbon atom of the biphenyl moiety is boned to a carbon or the nitrogen atom of the tetrazole moiety.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassTetrazoles
Direct ParentBiphenyltetrazoles and derivatives
Alternative Parents
Substituents
  • Biphenyltetrazole
  • Biphenyl
  • Phenylmethylamine
  • Benzylamine
  • Benzenoid
  • Imidazolinone
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • 2-imidazoline
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboximidamide
  • Carboxylic acid derivative
  • Carboxylic acid amidine
  • Amidine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of hypertension, as well as diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension. Irbesartan is also used as a second line agent in the treatment of congestive heart failure.
PharmacodynamicsAngiotensin II, the principal pressor agent of the renin-angiotensin system, is responsible for effects such as vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor and no agonist activity. Irbesartan's inhibition of angiotensin II binding to the AT1 receptor leads to multiple effects including vasodilation, a reduction in the secretion of vasopressin, and reduction in the production and secretion of aldosterone. The resulting effect is a decrease in blood pressure.
Mechanism of actionIrbesartan is a nonpeptide tetrazole derivative and an angiotensin II antagonist that selectively blocks the binding of angiotensin II to the AT1 receptor. In the renin-angiotensin system, angiotensin I is converted by angiotensin-converting enzyme (ACE) to form angiotensin II. Angiotensin II stimulates the adrenal cortex to synthesize and secrete aldosterone, which decreases the excretion of sodium and increases the excretion of potassium. Angiotensin II also acts as a vasoconstrictor in vascular smooth muscle. Irbesartan, by blocking the binding of angiotensin II to the AT1 receptor, promotes vasodilation and decreases the effects of aldosterone. The negative feedback regulation of angiotensin II on renin secretion is also inhibited, but the resulting rise in plasma renin concentrations and consequent rise in angiotensin II plasma concentrations do not counteract the blood pressure–lowering effect that occurs. The action of ARBs is different from ACE inhibitors, which block the conversion of angiotensin I to angiotensin II, meaning that the production of angiotensin II is not completely inhibited, as the hormone can be formed via other enzymes. Also, unlike ACE inhibitors, irbesartan and other ARBs do not interfere with response to bradykinins and substance P, which allows for the absence of adverse effects that are present in ACE inhibitors (eg. dry cough).
Related Articles
AbsorptionRapid and complete with an average absolute bioavailability of 60-80%. Food has no affect on bioavailability.
Volume of distribution
  • 53 to 93 L
Protein binding90% bound to serum proteins (primarily albumin and a1-acid glycoprotein) with negligible binding to cellular components of blood.
Metabolism

Hepatic. Irbesartan is metabolized via glucuronide conjugation and oxidation. In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.

SubstrateEnzymesProduct
Irbesartan
SR 49498Details
Irbesartan
Irbesartan derivative M4Details
Irbesartan
Irbesartan derivative M5Details
Irbesartan
Irbesartan derivative M7Details
Irbesartan
Not Available
Irbesartan derivative M3Details
Irbesartan
Irbesartan derivative M8Details
Irbesartan derivative M4
Irbesartan derivative M1Details
Irbesartan derivative M1
Not Available
Irbesartan derivative M2Details
Irbesartan derivative M7
Irbesartan derivative M1Details
Irbesartan derivative M5
Irbesartan derivative M1Details
Irbesartan derivative M4
Not Available
Irbesartan derivative M6Details
Irbesartan derivative M6
Not Available
Irbesartan derivative M2Details
Route of eliminationIrbesartan is metabolized via glucuronide conjugation and oxidation. Irbesartan and its metabolites are excreted by both biliary and renal routes. Irbesartan is excreted in the milk of lactating rats.
Half life11-15 hours
Clearance
  • 157-176 mL/min
ToxicityHypotension and tachycardia; bradycardia might also occur from overdose, LD50=mg/kg(orally in rat)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Irbesartan Action PathwayDrug actionSMP00161
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9271
Caco-2 permeable-0.5679
P-glycoprotein substrateSubstrate0.7046
P-glycoprotein inhibitor IInhibitor0.639
P-glycoprotein inhibitor IINon-inhibitor0.6458
Renal organic cation transporterNon-inhibitor0.5091
CYP450 2C9 substrateNon-substrate0.6401
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.5749
CYP450 1A2 substrateNon-inhibitor0.6782
CYP450 2C9 inhibitorInhibitor0.5928
CYP450 2D6 inhibitorNon-inhibitor0.7584
CYP450 2C19 inhibitorInhibitor0.6619
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6192
Ames testNon AMES toxic0.5238
CarcinogenicityNon-carcinogens0.7492
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7762 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9171
hERG inhibition (predictor II)Non-inhibitor0.7728
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Film-coated tabletOral use150 mg
Film-coated tabletOral use300 mg
Film-coated tabletOral use75 mg
Tablet, film coatedoral
Tabletoral150 mg
Tabletoral150 mg/1
Tabletoral300 mg
Tabletoral300 mg/1
Tabletoral75 mg/1
Tabletoral75 mg
Tabletoral150 mg/150mg
Tabletoral300 mg/300mg
Tabletoral75 mg/75mg
Tablet, coatedoral150 mg/1
Tablet, coatedoral300 mg/1
Tablet, coatedoral75 mg/1
Tablet, film coatedoral150 mg/1
Tablet, film coatedoral300 mg/1
Tablet, film coatedoral75 mg/1
Tabletoral
Film-coated tabletsOral use150 mg
Film-coated tabletsOral use300 mg
Film-coated tabletsOral use75 mg
TabletOral use150 mg
TabletOral use300 mg
TabletOral use75 mg
Prices
Unit descriptionCostUnit
Avalide 300-25 mg tablet3.92USD tablet
Avalide 300-12.5 mg tablet3.63USD tablet
Avalide 150-12.5 mg tablet3.33USD tablet
Avapro 300 mg tablet2.64USD tablet
Avapro 150 mg tablet2.33USD tablet
Avapro 75 mg tablet2.21USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2057913 No1997-07-082011-03-20Canada
CA2177772 No2007-04-102016-05-30Canada
US5270317 No1994-09-302011-09-30Us
US5994348 Yes1995-12-072015-12-07Us
US6342247 Yes1995-12-072015-12-07Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point180-181 °CNot Available
logP6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00884 mg/mLALOGPS
logP4.51ALOGPS
logP5.5ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)7.4ChemAxon
pKa (Strongest Basic)4.12ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area87.13 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity136.72 m3·mol-1ChemAxon
Polarizability47.59 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Gennady Nisnevich, “Novel synthesis of irbesartan.” U.S. Patent US20040192713, issued September 30, 2004.

US20040192713
General References
  1. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):851-60. [PubMed:11565517 ]
  2. Adams MA, Trudeau L: Irbesartan: review of pharmacology and comparative properties. Can J Clin Pharmacol. 2000 Spring;7(1):22-31. [PubMed:10822210 ]
  3. Croom KF, Curran MP, Goa KL, Perry CM: Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs. 2004;64(9):999-1028. [PubMed:15101793 ]
External Links
ATC CodesC09CA04C09DA04C09DB05
AHFS Codes
  • 24:32.08
PDB EntriesNot Available
FDA labelDownload (263 KB)
MSDSDownload (57.3 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Irbesartan.
AbirateroneThe serum concentration of Irbesartan can be increased when it is combined with Abiraterone.
AcebutololIrbesartan may increase the hypotensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Irbesartan is combined with Aceclofenac.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Irbesartan.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Irbesartan.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Irbesartan.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Irbesartan is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Adapalene.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Irbesartan.
AlfuzosinAlfuzosin may increase the hypotensive activities of Irbesartan.
AliskirenIrbesartan may increase the hypotensive activities of Aliskiren.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Irbesartan.
AlosetronThe metabolism of Alosetron can be decreased when combined with Irbesartan.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Irbesartan.
AlprenololAlprenolol may increase the hypotensive activities of Irbesartan.
AmbrisentanIrbesartan may increase the hypotensive activities of Ambrisentan.
AmifostineIrbesartan may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Irbesartan.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Irbesartan.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Irbesartan.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Irbesartan.
AmlodipineAmlodipine may increase the hypotensive activities of Irbesartan.
AmobarbitalAmobarbital may increase the hypotensive activities of Irbesartan.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Irbesartan.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Irbesartan.
Amyl NitriteThe risk or severity of adverse effects can be increased when Irbesartan is combined with Amyl Nitrite.
AntipyrineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Antipyrine.
ApixabanThe metabolism of Apixaban can be decreased when combined with Irbesartan.
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Irbesartan.
ApremilastThe risk or severity of adverse effects can be increased when Irbesartan is combined with Apremilast.
AprepitantThe metabolism of Irbesartan can be increased when combined with Aprepitant.
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Irbesartan.
ArdeparinArdeparin may increase the hyperkalemic activities of Irbesartan.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Irbesartan.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Irbesartan.
AripiprazoleAripiprazole may increase the hypotensive activities of Irbesartan.
ArtemetherThe metabolism of Artemether can be decreased when combined with Irbesartan.
AtazanavirThe metabolism of Atazanavir can be decreased when combined with Irbesartan.
AtenololAtenolol may increase the hypotensive activities of Irbesartan.
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Irbesartan.
AzapropazoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Azilsartan medoxomil.
BalsalazideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Balsalazide.
BarbitalBarbital may increase the hypotensive activities of Irbesartan.
BemiparinBemiparin may increase the hyperkalemic activities of Irbesartan.
BenazeprilBenazepril may increase the hypotensive activities of Irbesartan.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Irbesartan.
BenmoxinBenmoxin may increase the hypotensive activities of Irbesartan.
BenoxaprofenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Benoxaprofen.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Irbesartan.
BepridilIrbesartan may increase the hypotensive activities of Bepridil.
BeraprostThe metabolism of Beraprost can be decreased when combined with Irbesartan.
BetaxololBetaxolol may increase the hypotensive activities of Irbesartan.
BethanidineBethanidine may increase the hypotensive activities of Irbesartan.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Irbesartan.
BimatoprostBimatoprost may increase the hypotensive activities of Irbesartan.
BisoprololBisoprolol may increase the hypotensive activities of Irbesartan.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Irbesartan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Irbesartan.
BosentanBosentan may increase the hypotensive activities of Irbesartan.
BretyliumIrbesartan may increase the hypotensive activities of Bretylium.
BrimonidineIrbesartan may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Irbesartan.
BromfenacThe risk or severity of adverse effects can be increased when Irbesartan is combined with Bromfenac.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Irbesartan.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Irbesartan.
BupranololIrbesartan may increase the hypotensive activities of Bupranolol.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Irbesartan.
BupropionThe metabolism of Bupropion can be decreased when combined with Irbesartan.
CabazitaxelThe metabolism of Cabazitaxel can be decreased when combined with Irbesartan.
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Irbesartan.
CaffeineThe metabolism of Caffeine can be decreased when combined with Irbesartan.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Irbesartan.
CanagliflozinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Canagliflozin.
CandesartanCandesartan may increase the hypotensive activities of Irbesartan.
CandoxatrilCandoxatril may increase the hypotensive activities of Irbesartan.
CapecitabineThe metabolism of Irbesartan can be decreased when combined with Capecitabine.
CaptoprilIrbesartan may increase the hypotensive activities of Captopril.
CarbamazepineThe metabolism of Irbesartan can be increased when combined with Carbamazepine.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Irbesartan.
CaroxazoneCaroxazone may increase the hypotensive activities of Irbesartan.
CarprofenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Carprofen.
CarteololCarteolol may increase the hypotensive activities of Irbesartan.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Irbesartan.
CarvedilolCarvedilol may increase the hypotensive activities of Irbesartan.
CastanospermineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Irbesartan is combined with Celecoxib.
CelecoxibThe metabolism of Irbesartan can be decreased when combined with Celecoxib.
CeliprololIrbesartan may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Irbesartan can be increased when it is combined with Ceritinib.
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Irbesartan.
CertoparinCertoparin may increase the hyperkalemic activities of Irbesartan.
ChloroquineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Chloroquine.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Irbesartan.
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Irbesartan.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Irbesartan.
CholecalciferolThe metabolism of Irbesartan can be decreased when combined with Cholecalciferol.
CilazaprilIrbesartan may increase the hypotensive activities of Cilazapril.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Irbesartan.
CiprofloxacinIrbesartan may increase the arrhythmogenic activities of Ciprofloxacin.
CisaprideThe metabolism of Cisapride can be decreased when combined with Irbesartan.
ClevidipineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Clevidipine.
ClonidineClonidine may increase the hypotensive activities of Irbesartan.
ClonixinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Clonixin.
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Irbesartan.
ClotrimazoleThe metabolism of Irbesartan can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Clozapine can be decreased when combined with Irbesartan.
CryptenamineCryptenamine may increase the hypotensive activities of Irbesartan.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Irbesartan.
CyclosporineIrbesartan may increase the hyperkalemic activities of Cyclosporine.
CyclosporineThe metabolism of Irbesartan can be decreased when combined with Cyclosporine.
CyclothiazideCyclothiazide may increase the hypotensive activities of Irbesartan.
D-LimoneneThe risk or severity of adverse effects can be increased when Irbesartan is combined with D-Limonene.
DabrafenibThe serum concentration of Irbesartan can be decreased when it is combined with Dabrafenib.
DabrafenibThe metabolism of Dabrafenib can be decreased when combined with Irbesartan.
DalteparinDalteparin may increase the hyperkalemic activities of Irbesartan.
DapagliflozinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Irbesartan.
DapsoneThe metabolism of Dapsone can be decreased when combined with Irbesartan.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Irbesartan.
DebrisoquinIrbesartan may increase the hypotensive activities of Debrisoquin.
DeferasiroxThe serum concentration of Irbesartan can be increased when it is combined with Deferasirox.
DelavirdineThe metabolism of Irbesartan can be decreased when combined with Delavirdine.
DeserpidineIrbesartan may increase the hypotensive activities of Deserpidine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Irbesartan.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Irbesartan.
DiazepamThe metabolism of Diazepam can be decreased when combined with Irbesartan.
DiazoxideDiazoxide may increase the hypotensive activities of Irbesartan.
DiclofenacThe risk or severity of adverse effects can be increased when Irbesartan is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Diclofenamide.
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Irbesartan.
DiflunisalThe risk or severity of adverse effects can be increased when Irbesartan is combined with Diflunisal.
DiltiazemDiltiazem may increase the hypotensive activities of Irbesartan.
DinutuximabThe risk or severity of adverse effects can be increased when Irbesartan is combined with Dinutuximab.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Irbesartan.
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Irbesartan.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Irbesartan.
DomperidoneThe metabolism of Domperidone can be decreased when combined with Irbesartan.
DonepezilThe metabolism of Donepezil can be decreased when combined with Irbesartan.
DopamineThe metabolism of Dopamine can be decreased when combined with Irbesartan.
DorzolamideDorzolamide may increase the hypotensive activities of Irbesartan.
DoxazosinDoxazosin may increase the hypotensive activities of Irbesartan.
DoxepinThe metabolism of Doxepin can be decreased when combined with Irbesartan.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Irbesartan.
DrospirenoneIrbesartan may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Irbesartan is combined with Droxicam.
DuloxetineIrbesartan may increase the orthostatic hypotensive activities of Duloxetine.
EfavirenzThe metabolism of Irbesartan can be decreased when combined with Efavirenz.
EfonidipineIrbesartan may increase the hypotensive activities of Efonidipine.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Irbesartan.
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Irbesartan.
EmpagliflozinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Irbesartan.
EnalaprilatIrbesartan may increase the hypotensive activities of Enalaprilat.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Irbesartan.
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Irbesartan.
EpirizoleThe risk or severity of adverse effects can be increased when Irbesartan is combined with Epirizole.
EplerenoneEplerenone may increase the hyperkalemic activities of Irbesartan.
EplerenoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Eplerenone.
EpoprostenolIrbesartan may increase the hypotensive activities of Epoprostenol.
EprosartanEprosartan may increase the hypotensive activities of Irbesartan.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Irbesartan.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Irbesartan.
EstradiolThe metabolism of Estradiol can be decreased when combined with Irbesartan.
EstroneThe metabolism of Estrone can be decreased when combined with Irbesartan.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Irbesartan.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Irbesartan.
EtanerceptThe risk or severity of adverse effects can be increased when Irbesartan is combined with Etanercept.
EtodolacThe risk or severity of adverse effects can be increased when Irbesartan is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Irbesartan is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Irbesartan is combined with Etoricoxib.
EtravirineThe metabolism of Etravirine can be decreased when combined with Irbesartan.
Evening primrose oilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Irbesartan is combined with exisulind.
FelodipineFelodipine may increase the hypotensive activities of Irbesartan.
FenbufenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Fenbufen.
FenoldopamFenoldopam may increase the hypotensive activities of Irbesartan.
FenoprofenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Fenoprofen.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Irbesartan.
FloctafenineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Floctafenine.
FloxuridineThe metabolism of Irbesartan can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Irbesartan can be decreased when combined with Fluconazole.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Irbesartan.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Irbesartan.
FlunixinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Flunixin.
FluorouracilThe metabolism of Irbesartan can be decreased when combined with Fluorouracil.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Irbesartan.
FlurbiprofenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Flurbiprofen.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Irbesartan.
FluvoxamineThe metabolism of Irbesartan can be decreased when combined with Fluvoxamine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Irbesartan.
FosinoprilFosinopril may increase the hypotensive activities of Irbesartan.
FosphenytoinThe metabolism of Fosphenytoin can be decreased when combined with Irbesartan.
FurazolidoneFurazolidone may increase the hypotensive activities of Irbesartan.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Irbesartan.
GavestinelThe metabolism of Gavestinel can be decreased when combined with Irbesartan.
GemfibrozilThe metabolism of Irbesartan can be decreased when combined with Gemfibrozil.
GliclazideThe metabolism of Gliclazide can be decreased when combined with Irbesartan.
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Irbesartan.
GlipizideThe metabolism of Glipizide can be decreased when combined with Irbesartan.
GlyburideThe metabolism of Glyburide can be decreased when combined with Irbesartan.
GuanabenzGuanabenz may increase the hypotensive activities of Irbesartan.
GuanadrelGuanadrel may increase the hypotensive activities of Irbesartan.
GuanethidineIrbesartan may increase the hypotensive activities of Guanethidine.
GuanfacineGuanfacine may increase the hypotensive activities of Irbesartan.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Irbesartan.
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Irbesartan.
HalothaneThe metabolism of Halothane can be decreased when combined with Irbesartan.
HeparinHeparin may increase the hyperkalemic activities of Irbesartan.
HexamethoniumIrbesartan may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Irbesartan.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Irbesartan.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Irbesartan.
HMPL-004The risk or severity of adverse effects can be increased when Irbesartan is combined with HMPL-004.
HydracarbazineHydracarbazine may increase the hypotensive activities of Irbesartan.
HydralazineIrbesartan may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Irbesartan.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Irbesartan.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Irbesartan.
IbuprofenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Irbesartan is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Irbesartan is combined with Icatibant.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Irbesartan.
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Irbesartan.
IloprostIloprost may increase the hypotensive activities of Irbesartan.
ImatinibThe metabolism of Imatinib can be decreased when combined with Irbesartan.
IndapamideIndapamide may increase the hypotensive activities of Irbesartan.
IndenololIrbesartan may increase the hypotensive activities of Indenolol.
IndinavirThe metabolism of Irbesartan can be decreased when combined with Indinavir.
indisulamThe metabolism of indisulam can be decreased when combined with Irbesartan.
IndomethacinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Indomethacin.
IndoprofenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Indoprofen.
IndoraminIrbesartan may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Irbesartan.
IproniazidIproniazid may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Irbesartan.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Irbesartan.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Irbesartan.
IsoxicamThe risk or severity of adverse effects can be increased when Irbesartan is combined with Isoxicam.
IsoxsuprineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Irbesartan.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Irbesartan.
KebuzoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Kebuzone.
KetamineThe metabolism of Ketamine can be decreased when combined with Irbesartan.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Irbesartan.
KetoconazoleThe metabolism of Irbesartan can be decreased when combined with Ketoconazole.
KetoprofenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Irbesartan is combined with Ketorolac.
LabetalolLabetalol may increase the hypotensive activities of Irbesartan.
LacidipineIrbesartan may increase the hypotensive activities of Lacidipine.
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Irbesartan.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Irbesartan.
LatanoprostLatanoprost may increase the hypotensive activities of Irbesartan.
LeflunomideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Leflunomide.
LeflunomideThe metabolism of Irbesartan can be decreased when combined with Leflunomide.
LercanidipineLercanidipine may increase the hypotensive activities of Irbesartan.
LesinuradThe metabolism of Lesinurad can be decreased when combined with Irbesartan.
LevobunololThe risk or severity of adverse effects can be increased when Irbesartan is combined with Levobunolol.
LevodopaIrbesartan may increase the orthostatic hypotensive activities of Levodopa.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Irbesartan.
LicofeloneThe metabolism of Licofelone can be decreased when combined with Irbesartan.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Irbesartan.
LisinoprilLisinopril may increase the hypotensive activities of Irbesartan.
LithiumThe serum concentration of Lithium can be increased when it is combined with Irbesartan.
LofexidineIrbesartan may increase the hypotensive activities of Lofexidine.
LoperamideThe metabolism of Loperamide can be decreased when combined with Irbesartan.
LopinavirThe metabolism of Irbesartan can be decreased when combined with Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Irbesartan.
LornoxicamThe risk or severity of adverse effects can be increased when Irbesartan is combined with Lornoxicam.
LosartanLosartan may increase the hypotensive activities of Irbesartan.
LovastatinThe metabolism of Irbesartan can be decreased when combined with Lovastatin.
LoxoprofenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Loxoprofen.
LumacaftorThe serum concentration of Irbesartan can be decreased when it is combined with Lumacaftor.
LumiracoxibThe risk or severity of adverse effects can be increased when Irbesartan is combined with Lumiracoxib.
MacitentanIrbesartan may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Irbesartan is combined with Magnesium salicylate.
ManidipineIrbesartan may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Irbesartan.
MasoprocolThe risk or severity of adverse effects can be increased when Irbesartan is combined with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Irbesartan.
MecamylamineMecamylamine may increase the hypotensive activities of Irbesartan.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Irbesartan is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Irbesartan is combined with Mefenamic acid.
MelatoninThe metabolism of Melatonin can be decreased when combined with Irbesartan.
MeloxicamThe risk or severity of adverse effects can be increased when Irbesartan is combined with Meloxicam.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Irbesartan.
MesalazineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Mesalazine.
MestranolThe metabolism of Mestranol can be decreased when combined with Irbesartan.
MetamizoleThe risk or severity of adverse effects can be increased when Irbesartan is combined with Metamizole.
MethadoneThe metabolism of Methadone can be decreased when combined with Irbesartan.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Irbesartan.
MethohexitalMethohexital may increase the hypotensive activities of Irbesartan.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Irbesartan.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Irbesartan.
MethyldopaMethyldopa may increase the hypotensive activities of Irbesartan.
Methylene blueMethylene blue may increase the hypotensive activities of Irbesartan.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Irbesartan.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Irbesartan.
MetipranololIrbesartan may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Irbesartan.
MetoprololMetoprolol may increase the hypotensive activities of Irbesartan.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Irbesartan.
MibefradilIrbesartan may increase the hypotensive activities of Mibefradil.
MifepristoneThe serum concentration of Irbesartan can be increased when it is combined with Mifepristone.
MinaprineMinaprine may increase the hypotensive activities of Irbesartan.
MinoxidilMinoxidil may increase the hypotensive activities of Irbesartan.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Irbesartan.
MoclobemideMoclobemide may increase the hypotensive activities of Irbesartan.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Irbesartan.
MoexiprilMoexipril may increase the hypotensive activities of Irbesartan.
MolsidomineMolsidomine may increase the hypotensive activities of Irbesartan.
MontelukastThe metabolism of Montelukast can be decreased when combined with Irbesartan.
MorphineThe metabolism of Morphine can be decreased when combined with Irbesartan.
MoxonidineIrbesartan may increase the hypotensive activities of Moxonidine.
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Irbesartan.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Irbesartan is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Irbesartan is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nabumetone.
NadololIrbesartan may increase the hypotensive activities of Nadolol.
NadroparinNadroparin may increase the hyperkalemic activities of Irbesartan.
NaftifineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Naftifine.
NaloxoneThe metabolism of Naloxone can be decreased when combined with Irbesartan.
NaproxenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Naproxen.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Irbesartan.
NCX 4016The risk or severity of adverse effects can be increased when Irbesartan is combined with NCX 4016.
NebivololIrbesartan may increase the hypotensive activities of Nebivolol.
NepafenacThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nepafenac.
NesiritideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nesiritide.
NetupitantThe metabolism of Netupitant can be decreased when combined with Irbesartan.
NevirapineThe metabolism of Nevirapine can be decreased when combined with Irbesartan.
NialamideNialamide may increase the hypotensive activities of Irbesartan.
NicardipineNicardipine may increase the hypotensive activities of Irbesartan.
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Irbesartan.
NicorandilNicorandil may increase the hypotensive activities of Irbesartan.
NicotineThe metabolism of Nicotine can be decreased when combined with Irbesartan.
NifedipineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nifedipine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Irbesartan is combined with Niflumic Acid.
NiguldipineIrbesartan may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Irbesartan can be decreased when combined with Nilotinib.
NilvadipineIrbesartan may increase the hypotensive activities of Nilvadipine.
NimesulideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Irbesartan.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Irbesartan.
NisoldipineNisoldipine may increase the hypotensive activities of Irbesartan.
NitrendipineIrbesartan may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Irbesartan.
NitroprussideNitroprusside may increase the hypotensive activities of Irbesartan.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Irbesartan.
ObinutuzumabIrbesartan may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Irbesartan.
OlmesartanOlmesartan may increase the hypotensive activities of Irbesartan.
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Irbesartan.
OlopatadineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Olopatadine.
OlsalazineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Olsalazine.
OmapatrilatOmapatrilat may increase the hypotensive activities of Irbesartan.
OmbitasvirThe metabolism of Ombitasvir can be decreased when combined with Irbesartan.
OmeprazoleThe metabolism of Irbesartan can be decreased when combined with Omeprazole.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Irbesartan.
OrgoteinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Orgotein.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Irbesartan.
OxaprozinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Oxaprozin.
OxprenololIrbesartan may increase the hypotensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Oxyphenbutazone.
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Irbesartan.
PapaverineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Papaverine.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Irbesartan.
ParecoxibThe risk or severity of adverse effects can be increased when Irbesartan is combined with Parecoxib.
PargylineIrbesartan may increase the hypotensive activities of Pargyline.
ParnaparinParnaparin may increase the hyperkalemic activities of Irbesartan.
PazopanibThe metabolism of Pazopanib can be decreased when combined with Irbesartan.
PenbutololIrbesartan may increase the hypotensive activities of Penbutolol.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Irbesartan.
PentobarbitalPentobarbital may increase the hypotensive activities of Irbesartan.
PentoliniumIrbesartan may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Irbesartan.
PerindoprilPerindopril may increase the hypotensive activities of Irbesartan.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Irbesartan.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Irbesartan.
PhenelzinePhenelzine may increase the hypotensive activities of Irbesartan.
PheniprazinePheniprazine may increase the hypotensive activities of Irbesartan.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Irbesartan.
PhenobarbitalThe metabolism of Phenobarbital can be decreased when combined with Irbesartan.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Irbesartan.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Irbesartan.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Irbesartan.
PhentolaminePhentolamine may increase the hypotensive activities of Irbesartan.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Phenylbutazone.
PhenytoinThe metabolism of Phenytoin can be decreased when combined with Irbesartan.
PimecrolimusThe risk or severity of adverse effects can be increased when Irbesartan is combined with Pimecrolimus.
PinacidilIrbesartan may increase the hypotensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Irbesartan.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Irbesartan.
PirfenidoneThe risk or severity of adverse effects can be increased when Irbesartan is combined with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Irbesartan.
PiroxicamThe risk or severity of adverse effects can be increased when Irbesartan is combined with Piroxicam.
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Irbesartan.
PivhydrazinePivhydrazine may increase the hypotensive activities of Irbesartan.
PolythiazideIrbesartan may increase the hypotensive activities of Polythiazide.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Irbesartan.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Irbesartan.
PravastatinThe metabolism of Pravastatin can be decreased when combined with Irbesartan.
PrazosinPrazosin may increase the hypotensive activities of Irbesartan.
PrimidonePrimidone may increase the hypotensive activities of Irbesartan.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Irbesartan.
ProguanilThe metabolism of Proguanil can be decreased when combined with Irbesartan.
PromazineThe metabolism of Promazine can be decreased when combined with Irbesartan.
PropacetamolThe risk or severity of adverse effects can be increased when Irbesartan is combined with Propacetamol.
PropofolThe metabolism of Propofol can be decreased when combined with Irbesartan.
PropranololPropranolol may increase the hypotensive activities of Irbesartan.
PTC299The risk or severity of adverse effects can be increased when Irbesartan is combined with PTC299.
PyrimethamineThe metabolism of Irbesartan can be decreased when combined with Pyrimethamine.
QuazepamThe metabolism of Quazepam can be decreased when combined with Irbesartan.
QuetiapineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Quetiapine.
QuinaprilQuinapril may increase the hypotensive activities of Irbesartan.
QuinidineThe metabolism of Quinidine can be decreased when combined with Irbesartan.
QuinineQuinine may increase the hypotensive activities of Irbesartan.
QuinineThe metabolism of Quinine can be decreased when combined with Irbesartan.
RabeprazoleThe metabolism of Irbesartan can be decreased when combined with Rabeprazole.
RamiprilRamipril may increase the hypotensive activities of Irbesartan.
RasagilineRasagiline may increase the hypotensive activities of Irbesartan.
RemikirenRemikiren may increase the hypotensive activities of Irbesartan.
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Irbesartan.
RescinnamineIrbesartan may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Irbesartan.
ResveratrolThe risk or severity of adverse effects can be increased when Irbesartan is combined with Resveratrol.
ReviparinReviparin may increase the hyperkalemic activities of Irbesartan.
RifampicinThe metabolism of Rifampicin can be decreased when combined with Irbesartan.
RifapentineThe metabolism of Irbesartan can be increased when combined with Rifapentine.
RiociguatIrbesartan may increase the hypotensive activities of Riociguat.
RisperidoneIrbesartan may increase the hypotensive activities of Risperidone.
RitonavirThe metabolism of Irbesartan can be decreased when combined with Ritonavir.
RituximabIrbesartan may increase the hypotensive activities of Rituximab.
RofecoxibThe risk or severity of adverse effects can be increased when Irbesartan is combined with Rofecoxib.
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Irbesartan.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Irbesartan.
SafrazineSafrazine may increase the hypotensive activities of Irbesartan.
SalicylamideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Irbesartan is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Irbesartan is combined with Salsalate.
SaprisartanIrbesartan may increase the hypotensive activities of Saprisartan.
SecobarbitalSecobarbital may increase the hypotensive activities of Irbesartan.
SelegilineSelegiline may increase the hypotensive activities of Irbesartan.
SelegilineThe metabolism of Selegiline can be decreased when combined with Irbesartan.
SelexipagIrbesartan may increase the hypotensive activities of Selexipag.
SeratrodastThe risk or severity of adverse effects can be increased when Irbesartan is combined with Seratrodast.
SertralineThe metabolism of Sertraline can be decreased when combined with Irbesartan.
SildenafilSildenafil may increase the antihypertensive activities of Irbesartan.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Irbesartan.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Irbesartan.
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Irbesartan.
SitaxentanIrbesartan may increase the hypotensive activities of Sitaxentan.
SorafenibThe metabolism of Irbesartan can be decreased when combined with Sorafenib.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Irbesartan.
SpiraprilIrbesartan may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Irbesartan.
SRT501The risk or severity of adverse effects can be increased when Irbesartan is combined with SRT501.
StiripentolThe metabolism of Irbesartan can be decreased when combined with Stiripentol.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Irbesartan.
SulfamethoxazoleThe metabolism of Irbesartan can be decreased when combined with Sulfamethoxazole.
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Irbesartan.
SulfasalazineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Sulfasalazine.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Irbesartan.
SulfisoxazoleThe metabolism of Sulfisoxazole can be decreased when combined with Irbesartan.
SulindacThe risk or severity of adverse effects can be increased when Irbesartan is combined with Sulindac.
SuprofenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Suprofen.
TadalafilTadalafil may increase the antihypertensive activities of Irbesartan.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Irbesartan.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Irbesartan.
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Irbesartan.
TelmisartanTelmisartan may increase the hypotensive activities of Irbesartan.
TemazepamThe metabolism of Temazepam can be decreased when combined with Irbesartan.
TemocaprilIrbesartan may increase the hypotensive activities of Temocapril.
TenoxicamThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tenoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tepoxalin.
TerazosinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Terazosin.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Irbesartan.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Irbesartan.
TeriflunomideThe risk or severity of adverse effects can be increased when Irbesartan is combined with Teriflunomide.
TeriflunomideThe metabolism of Irbesartan can be decreased when combined with Teriflunomide.
TerlipressinIrbesartan may increase the hypotensive activities of Terlipressin.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Irbesartan.
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Irbesartan.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Irbesartan.
ThiamylalThiamylal may increase the hypotensive activities of Irbesartan.
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Irbesartan.
ThiopentalThiopental may increase the hypotensive activities of Irbesartan.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Irbesartan.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tiaprofenic acid.
TiboloneIrbesartan may increase the hypotensive activities of Tibolone.
TicagrelorThe metabolism of Irbesartan can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Irbesartan can be decreased when combined with Ticlopidine.
TicrynafenIrbesartan may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Irbesartan.
TinzaparinTinzaparin may increase the hyperkalemic activities of Irbesartan.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Irbesartan.
TolazolineTolazoline may increase the hypotensive activities of Irbesartan.
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Irbesartan.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Irbesartan.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Irbesartan.
TolvaptanTolvaptan may increase the hyperkalemic activities of Irbesartan.
TorasemideTorasemide may increase the hypotensive activities of Irbesartan.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Irbesartan.
TrandolaprilTrandolapril may increase the hypotensive activities of Irbesartan.
TranilastThe risk or severity of adverse effects can be increased when Irbesartan is combined with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Irbesartan.
TranylcypromineTranylcypromine may increase the hypotensive activities of Irbesartan.
TravoprostTravoprost may increase the hypotensive activities of Irbesartan.
TreprostinilTreprostinil may increase the hypotensive activities of Irbesartan.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Irbesartan.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Irbesartan.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Irbesartan.
TrimazosinIrbesartan may increase the hypotensive activities of Trimazosin.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Irbesartan.
TrimethaphanIrbesartan may increase the hypotensive activities of Trimethaphan.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Irbesartan.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Irbesartan.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Irbesartan.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Irbesartan is combined with Trisalicylate-choline.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Irbesartan.
UdenafilUdenafil may increase the antihypertensive activities of Irbesartan.
UnoprostoneIrbesartan may increase the hypotensive activities of Unoprostone.
ValdecoxibThe risk or severity of adverse effects can be increased when Irbesartan is combined with Valdecoxib.
Valproic AcidThe metabolism of Irbesartan can be decreased when combined with Valproic Acid.
ValsartanValsartan may increase the hypotensive activities of Irbesartan.
VardenafilVardenafil may increase the antihypertensive activities of Irbesartan.
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Irbesartan.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Irbesartan.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Irbesartan.
VismodegibThe metabolism of Vismodegib can be decreased when combined with Irbesartan.
VoriconazoleThe metabolism of Irbesartan can be decreased when combined with Voriconazole.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Irbesartan.
WarfarinThe metabolism of Warfarin can be decreased when combined with Irbesartan.
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Irbesartan.
XylometazolineIrbesartan may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Irbesartan.
ZafirlukastThe metabolism of Irbesartan can be decreased when combined with Zafirlukast.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Irbesartan.
ZaltoprofenThe risk or severity of adverse effects can be increased when Irbesartan is combined with Zaltoprofen.
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Irbesartan.
ZileutonThe risk or severity of adverse effects can be increased when Irbesartan is combined with Zileuton.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Irbesartan.
ZomepiracThe risk or severity of adverse effects can be increased when Irbesartan is combined with Zomepirac.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Irbesartan.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
AGTR1
Uniprot ID:
P30556
Molecular Weight:
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Voigt JP, Bramlage P, Fink H: Hypophagic effect of the angiotensin AT1 receptor antagonist irbesartan in rats. Eur J Pharmacol. 2007 Jun 14;564(1-3):131-7. Epub 2007 Mar 3. [PubMed:17408613 ]
  3. Waeber B, Burnier M: AT1-receptor antagonism in hypertension: what has been learned with irbesartan? Expert Rev Cardiovasc Ther. 2003 May;1(1):23-33. [PubMed:15030294 ]
  4. Dol F, Martin G, Staels B, Mares AM, Cazaubon C, Nisato D, Bidouard JP, Janiak P, Schaeffer P, Herbert JM: Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2001 Sep;38(3):395-405. [PubMed:11486244 ]
  5. Martin G, Dol F, Mares AM, Berezowski V, Staels B, Hum DW, Schaeffer P, Herbert JM: Lesion progression in apoE-deficient mice: implication of chemokines and effect of the AT1 angiotensin II receptor antagonist irbesartan. J Cardiovasc Pharmacol. 2004 Feb;43(2):191-9. [PubMed:14716205 ]
  6. van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In 't Veld AJ, et al.: Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension. Hypertension. 1995 Jan;25(1):22-9. [PubMed:7843749 ]
  7. Carraway JW, Park S, McCune SA, Holycross BJ, Radin MJ: Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats. J Cardiovasc Pharmacol. 1999 Mar;33(3):451-60. [PubMed:10069682 ]
  8. Hope S, Brecher P, Chobanian AV: Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis. Am J Hypertens. 1999 Jan;12(1 Pt 1):28-34. [PubMed:10075381 ]
  9. Mazzolai L, Maillard M, Rossat J, Nussberger J, Brunner HR, Burnier M: Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists. Hypertension. 1999 Mar;33(3):850-5. [PubMed:10082498 ]
  10. Morsing P, Adler G, Brandt-Eliasson U, Karp L, Ohlson K, Renberg L, Sjoquist PO, Abrahamsson T: Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension. 1999 Jun;33(6):1406-13. [PubMed:10373224 ]
  11. Adams MA, Trudeau L: Irbesartan: review of pharmacology and comparative properties. Can J Clin Pharmacol. 2000 Spring;7(1):22-31. [PubMed:10822210 ]
  12. Croom KF, Plosker GL: Irbesartan: a review of its use in hypertension and diabetic nephropathy. Drugs. 2008;68(11):1543-69. [PubMed:18627212 ]
  13. Croom KF, Curran MP, Goa KL, Perry CM: Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs. 2004;64(9):999-1028. [PubMed:15101793 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Transcriptional activator activity, rna polymerase ii transcription factor binding
Specific Function:
Transcription factor that recognizes and binds to the enhancer heptamer motif 5'-TGA[CG]TCA-3'. Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation.
Gene Name:
JUN
Uniprot ID:
P05412
Molecular Weight:
35675.32 Da
References
  1. Zhu ZS, Wang JM, Chen SL: Mesenteric artery remodeling and effects of imidapril and irbesartan on it in spontaneously hypertensive rats. World J Gastroenterol. 2004 May 15;10(10):1471-5. [PubMed:15133856 ]
  2. Cheng SM, Yang SP, Ho LJ, Tsao TP, Chang DM, Lai JH: Irbesartan inhibits human T-lymphocyte activation through downregulation of activator protein-1. Br J Pharmacol. 2004 Jul;142(6):933-42. Epub 2004 Jun 21. [PubMed:15210574 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A3
Uniprot ID:
P35503
Molecular Weight:
60337.835 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 24, 2016 02:17